Home
/
Gut Health

Indole-3-propionic Acid: A Microbiome-Made Molecule Worth Measuring

REVIEWED BY
William Maish, MD MBA MPH
Clinical Product Lead
Published
November 4, 2025
Last updated
June 4, 2026
Key takeaway:

Measures indole-3-propionic acid (I3P), a gut microbiome–derived antioxidant and neuroprotective metabolite, to reveal microbiome signals relevant to brain, metabolic, and gut health. Low I3P levels have been linked in studies to increased oxidative stress and higher risk of cognitive decline and metabolic dysfunction, so tracking I3P can help guide lifestyle, dietary, or clinical interventions to reduce those risks.

Read more →
Table of contents

A microbiome-made molecule worth measuring

The indole‑3‑propionic acid test measures the concentration of IPA—a small molecule made primarily by certain intestinal bacteria from the amino acid tryptophan—in blood (serum or plasma) or urine. Most labs quantify IPA with high‑specificity methods like liquid chromatography–tandem mass spectrometry (LC‑MS/MS). Because IPA is produced by your microbes rather than by human cells, it serves as a functional readout of microbial metabolism, especially from anaerobes such as Clostridium sporogenes. Results reflect your current ecosystem and inputs (diet, medications, stress), not a fixed trait.

Why a single metabolite connects so many dots

Why it matters: IPA is a potent antioxidant and a signaling molecule. In experimental models, it scavenges harmful free radicals and activates receptors (like PXR) that help tighten intestinal barriers and modulate inflammation. Observational human studies link higher circulating IPA with healthier glucose regulation and lower future risk of type 2 diabetes, and with markers of liver and cardiovascular health, though causation has not been proven. IPA may also cross the blood–brain barrier and has been studied for neuroprotection. In short, this single metabolite connects your microbiome’s behavior to digestion, immunity, and metabolism.

In real life, we feel microbiome changes as symptoms or performance dips: meals that sit heavy, skin that flares, workouts that don’t recover as smoothly. An IPA test translates some of that biologic noise into a readable signal. Low IPA can accompany lower microbial diversity, diminished fiber fermentation, and increased gut permeability—all patterns that may track with bloating, irregularity, fatigue, or metabolic drift. It can also clarify the after‑effects of antibiotics, ultra‑low‑carb or highly restrictive diets, acute infections, or life stress, when microbial metabolism often shifts. Timing matters: IPA is especially informative when you are troubleshooting persistent GI issues, checking in after a big dietary change, or evaluating how your gut is responding to a new routine.

Zooming out, the gut microbiome touches nearly every system—glucose regulation, systemic inflammation, even mood signaling through the gut–brain axis. Watching IPA over time helps you see how fiber intake, fermented foods, or stress management influence microbial function. It is not about chasing a perfect number; it is about pattern recognition that supports prevention and long‑term resilience. If you have heard friends talk about collagen for skin or Ozempic for appetite, think of IPA as the quiet meter for something more foundational: how well your microbes turn everyday foods into protective chemistry.

Translating your concentration

Your report typically shows an IPA concentration (for example, ng/mL or μmol/L in blood, or a urine value often normalized to creatinine) compared with a reference range from a healthy population. In general, “balanced” patterns feature IPA in or near the lab’s reference interval, reflecting active microbial conversion of dietary tryptophan—usually supported by consistent intake of plant fibers and a stable, diverse microbiome. Lower‑than‑expected IPA suggests reduced production, which can occur with recent antibiotics, low fiber availability, suppressed producer species, or higher oxidative and inflammatory stress in the gut environment.

When IPA sits comfortably in range, it often aligns with efficient digestion, a more intact gut barrier, and a quieter inflammatory tone. Those conditions favor the production of short‑chain fatty acids (SCFAs) by other microbes as well, which together support glucose handling and lipid metabolism. “Optimal” varies person to person, shaped by genetics, geography, and habitual diet, so a single snapshot should be read in context rather than treated as a verdict.

When IPA is low, the signal is not a diagnosis—it is a prompt to consider mechanisms. Are fiber and polyphenols reaching the colon where producer microbes live? Has there been recent antimicrobial or acid‑suppressing medication use? Are symptoms or other labs hinting at mucosal inflammation or increased permeability? In some settings, very low IPA has been observed alongside insulin resistance, fatty liver risk, or active gut inflammation, but associations do not prove causation and clinical evaluation is essential if symptoms persist. Markedly high values are uncommon and may reflect assay differences, sample timing, or unusual diet patterns; your clinician will interpret these in context.

What an IPA test adds and doesn't

The bottom line: the indole‑3‑propionic acid test gives you a clear, quantifiable window into how your gut microbes are performing today. Read alongside your history, symptoms, and complementary labs, it helps convert everyday choices—like the plants on your plate or the recovery time you protect—into measurable shifts in gut‑driven chemistry that supports long‑term health.

FAQs

Indole-3-propionic acid test analyzes the genetic material of bacteria, fungi, and other microorganisms in stool to identify species diversity, abundance, and functional potential.

Results report the composition and balance of the gut microbiome—which microbes are present, their relative amounts, and inferred functional capabilities—and indicate microbial balance rather than diagnosing or proving the presence of disease.

An indole-3-propionic acid test is collected with a simple at‑home stool sample kit: you use the small swab or vial provided to collect a tiny amount of stool exactly as the kit instructions show, secure the sample in the provided container, and prepare it for return or drop‑off per the kit’s shipping directions.

Maintain cleanliness (wash hands before and after, avoid contaminating the swab or vial), clearly label the sample with the required information, and follow the printed instructions precisely—proper collection, storage, and timely return are essential for accurate sequencing results.

Indole-3-propionic acid (IPA) is a gut-derived metabolite produced from dietary tryptophan, so test results can provide insight into gut microbial activity and related processes — including digestion, intestinal inflammation or oxidative stress, nutrient absorption, metabolism, and gut–brain communication. Higher or lower IPA levels may reflect differences in microbiome function, dietary tryptophan availability, or metabolic pathways that influence these systems.

Microbiome patterns and IPA levels can correlate with certain physiological states or risks but do not by themselves diagnose specific diseases. IPA results are one piece of the clinical picture and should be interpreted alongside symptoms, other lab tests, and medical history in consultation with a healthcare professional.

Next‑generation sequencing (NGS) can provide high‑resolution data on the composition and genetic potential of the gut microbiome, which helps identify organisms and pathways associated with indole‑3‑propionic acid (IPA) production; however, translating those microbial signatures into a definitive IPA result is probabilistic because actual metabolite levels depend on gene expression, microbial interactions and host biology, not just which microbes are present.

IPA test results should be viewed as a snapshot in time and can change with recent diet, stress, or antibiotic use (as well as sample timing and handling), so results may vary and are best interpreted alongside clinical context and repeat or complementary testing when needed.

Many people test their indole-3-propionic acid once per year to establish a baseline, and test every 3–6 months if they are actively adjusting diet, probiotics, or other interventions that might affect levels.

Comparing trends over time is more valuable than a one-off reading—look at direction and magnitude of change using consistent testing methods and note concurrent lifestyle or treatment changes.

Yes — microbial populations, including those that produce indole-3-propionic acid (IPA), can shift within days in response to dietary or lifestyle changes, but those early changes are often transient; more stable patterns typically emerge over weeks to months as the gut ecosystem re‑equilibrates.

For meaningful comparisons, keep diet and lifestyle consistent for several weeks before retesting and prefer repeat measurements spaced weeks to months rather than single short‑interval samples to detect true, sustained changes in IPA levels.

References

  1. Sehgal, R., de Mello, V. D., Männistö, V., Lindström, J., Tuomilehto, J., Pihlajamäki, J., & Uusitupa, M. (2022). Indolepropionic acid, a gut bacteria-produced tryptophan metabolite and the risk of type 2 diabetes and non-alcoholic fatty liver disease. Nutrients, 14(21), 4695. https://doi.org/10.3390/nu14214695
  2. Mann, E. R., Lam, Y. K., & Uhlig, H. H. (2024). Short-chain fatty acids: Linking diet, the microbiome and immunity. Nature Reviews Immunology, 24(8), 577-595. https://doi.org/10.1038/s41577-024-01014-8
  3. Jovel, J., Patterson, J., Wang, W., Hotte, N., O'Keefe, S., Mitchel, T., Perry, T., Kao, D., Mason, A. L., Madsen, K. L., & Wong, G. K. (2016). Characterization of the gut microbiome using 16S or shotgun metagenomics. Frontiers in Microbiology, 7, 459. https://doi.org/10.3389/fmicb.2016.00459
  4. Lynch, S. V., & Pedersen, O. (2016). The human intestinal microbiome in health and disease. New England Journal of Medicine, 375(24), 2369-2379. https://doi.org/10.1056/NEJMra1600266
  5. Allaband, C., McDonald, D., Vázquez-Baeza, Y., Minich, J. J., Tripathi, A., Brenner, D. A., Loomba, R., Smarr, L., Sandborn, W. J., Schnabl, B., Dorrestein, P., Zarrinpar, A., & Knight, R. (2019). Microbiome 101: Studying, analyzing, and interpreting gut microbiome data for clinicians. Clinical Gastroenterology and Hepatology, 17(2), 218-230. https://doi.org/10.1016/j.cgh.2018.09.017

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey